/https://i.s3.glbimg.com/v1/AUTH_da025474c0c44edd99332dddb09cabe8/internal_photos/bs/2023/v/O/VU5ZZuSH6CPinBOmpmUg/32757252397-78c0c208cc-k.jpg)
Among the different types of cancer known to medicine, few represent as great a challenge as pancreatic cancer. This occurs not only due to the tumor’s often aggressive behavior, but mainly due to the silent way in which it usually develops.
Unlike many other tumors, pancreatic cancer rarely causes clear symptoms in the early stages. This characteristic makes early diagnosis more difficult and explains why, in many cases, the disease is only identified when it is more advanced.
The pancreas is a small, inconspicuous organ located deep in the abdomen, behind the stomach. Although little remembered in everyday life, it performs fundamental functions for the body. It produces enzymes that participate in the digestion of food and also important hormones, such as insulin, responsible for regulating blood sugar.
Changes in this organ do not always produce obvious signs. When symptoms such as weight loss, tiredness, abdominal pain or yellowish skin appear, the disease is often already at a more advanced stage. It is estimated that around 80% of patients receive the diagnosis at this stage.
Every year, more than half a million people around the world are diagnosed with this cancer. Currently, the average five-year survival rate is around 12%. Although it is still lower than that observed in other types, this number has been increasing progressively in recent decades — a direct reflection of advances in medical research.
Some factors increase the risk of developing pancreatic cancer, such as smoking, obesity, excessive alcohol consumption, physical inactivity and family history. Recognizing these factors is important not only for prevention, but also for identifying people who may benefit from more careful medical monitoring.
Medicine is beginning to enter a new phase in tackling this tumor. So-called precision medicine, for example, makes it possible to analyze cancer DNA and identify specific mutations that can guide more targeted treatments. In some patients, genetic changes already make it possible to use drugs originally developed for other types of tumors.
Technology is also starting to play an important role. Artificial intelligence systems are already capable of analyzing image exams, such as CT scans and MRIs, with great precision, allowing for increasingly earlier diagnoses.
Furthermore, new minimally invasive local therapies have been studied. These include approaches that use radiation or electrical pulses to treat the tumor without the need for conventional surgery. Methods such as radiosurgery and irreversible electroporation have already been applied in specific situations.
Radiosurgery uses highly concentrated beams of radiation to target the tumor with great precision, sparing the surrounding healthy tissue as much as possible. Irreversible electroporation — known as the NanoKnife system — employs high-intensity electrical pulses that alter the membrane of tumor cells, leading to their destruction without producing significant heat. These approaches may be especially useful in tumors located near delicate vascular structures.
None of these advances alone eliminates the challenges of pancreatic cancer. But together they show that we are facing a gradual change in the disease scenario.
The history of oncology reveals that many tumors considered extremely difficult in the past have become progressively more treatable as scientific knowledge has advanced. There is reason to believe that pancreatic cancer may also begin to follow this path.
